Lidanserin
Lidanserin (INN; ZK-33,839) is a drug which acts as a combined 5-HT2A and α1-adrenergic receptor antagonist.[1][2] It was developed as an antihypertensive agent but was never marketed.[1][2]
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C26H31FN2O4 |
Molar mass | 454.534 g/mol g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
See also
References
- Richard C. Allen (1989). Annual Reports in Medicinal Chemistry. Academic Press. p. 56. ISBN 978-0-12-040524-4. Retrieved 6 May 2012.
- American Chemical Society; American Chemical Society. Chemical Abstracts Service (27 February 1989). Chemical abstracts. American Chemical Society. p. 114. Retrieved 6 May 2012.
Sympatholytics (antagonize α-adrenergic vasoconstriction) |
| ||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Other antagonists |
| ||||||||||||||||||||||||||
|
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.